Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options

  title={Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options},
  author={Mattia Rosso and Shrishti Saxena and Tanuja Chitnis},
  journal={Expert Review of Neurotherapeutics},
  pages={509 - 516}
ABSTRACT Introduction: Recent research has shown that IL-6 receptor (IL-6 R) inhibitors like tocilizumab and satralizumab are effective in reducing the relapse rate in patients with NMOSD. Areas covered: This review article explores current concepts in NMOSD management and focuses on IL-6 R as a therapeutic target. The authors delve into the biological and immunological role of IL-6 in the pathogenesis of NMOSD. Further, the authors summarize the most recent findings on the use of anti-IL-6 R… Expand
Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: implications from immunology, the FcRn pathway and clinical experience.
The immunological basis of IL-6 blockade in NMOSD is introduced, the aim of extending the half-life of monoclonal antibodies (mAbs) has been actualized by successful clinical translation for Satralizumab and the basic principles of FcRn are highlighted in this review together with the potential therapeutic benefits of this emerging technology. Expand
Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder
In NMOSD patients with antibodies against aquaporin 4, monoclonal antibodies that deplete B cells (rituximab and inebilizumab) or interfere with interleukin 6 signaling or complement activation (eculizumAB) have superior efficacy compared to placebo. Expand
Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders
Satralizumab appears to be safe and effective as monotherapy or in combination with an immunosuppressant for patients with NMOSD and has the potential to become a valuable treatment option for these patients. Expand
Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects
Currently available therapeutic strategies for NMO as well as ongoing research in this field are presented, with reference to key points of immune-mediated processes involved in the background of the disease. Expand
Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders
Anti–IL-6 therapies might have a potential to reduce neuropathic pain, but further investigations are warranted to clarify the effect of inhibition of IL-6 signaling on neuropathicPain associated with MS and NMOSD. Expand
Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development
Using an IL- 6 inhibitor agent to prevent dTAA formation and progression showed promising results and suggests that using the IL-6 inhibitors in susceptible persons can be considered a lifesaving therapeutic approach. Expand


Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica
This study provides Class IV evidence that in patients with NMO, TCZ reduces relapse rate, neuropathic pain, and fatigue, and Class III evidence that Interleukin-6 receptor blockade is a promising therapeutic option for NMO. Expand
Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
Prolonged tocilizumab therapy may be safe and effective from early treatment phases onward for otherwise therapy-resistant highly active NMO and NMO spectrum disorder. Expand
Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.
Interleukin 6 receptor-blocking therapy can be effective in therapy-resistant cases of NMO and larger controlled studies are needed to confirm the efficacy of tocilizumab. Expand
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
Abstract Neuromyelitis optica (NMO) is a disabling autoimmune disease associated with an elevation of anti-aquaporin 4 (AQP4) autoantibodies. Here, we present a case with NMO who responded to monthlyExpand
Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications
This review focuses on the current advances in NMO immunological research, particularly that of cytokines and chemokines, and assessment of these useful biomarkers may become a supportive criterion for diagnosing NMO. Expand
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Among patients with NMOSD, satralizumab added to immunosuppressant treatment led to a lower risk of relapse than placebo but did not differ from placebo in its effect on pain or fatigue. Expand
Treatment of Neuromyelitis Optica: Review and Recommendations.
This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices. Expand
Neuromyelitis optica spectrum disorders: Emerging therapies
Standard immunotherapy, immunosuppressive agents, and corticosteroids can prevent acute attacks and maintain remission in the majority of patients with NMOSD, but there is a strong need for alternative options for patients who are refractory to standard treatments. Expand
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders.
Effectiveness of subcutaneous TCZ in NMOSD appears to be similar to that reported for the IV formulation and has an advantage of at-home administration. Expand
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
Different immunological status and pathophysiologies exist between NMO and MS, and IL-6 may play important roles in the pathogenesis of NMO. Expand